Skip to main content

Table 1 Recent and ongoing phase 3 trials of antiangiogenic agents for the treatment of mCRC

From: Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy

Trial

ClinicalTrials.gov identifier

Biologics

 

Bevacizumab in combination with crossover fluoropyrimidine-based chemotherapy beyond progression (stratum 1: AIO-IRI, FOLFIRI, CAPIRI or XELIRI; stratum 2: FUFOX, FOLFOX, CAPOX or XELOX) (ML 18147 study)*

NCT00700102

Aflibercept plus irinotecan and 5-FU following failure of an oxaliplatin-based regimen (VELOUR)

NCT00561470

Ramucirumab plus FOLFIRI following progression with first-line bevacizumab, oxaliplatin, and fluoropyrimidine

NCT01183780

TKIs

 

Brivanib alaninate in combination with the EGFR monoclonal antibody cetuximab following previous chemotherapy

NCT00640471

Cediranib plus chemotherapy (FOLFOX or XELOX) as first-line treatment (HORIZON II)

NCT00399035

Cediranib plus FOLFOX vs bevacizumab plus FOLFOX as first-line treatment (HORIZON III)

NCT00384176

Regorafenib plus best supportive care following failure of standard therapies (CORRECT)

NCT01103323

Sunitinib plus FOLFIRI as first-line treatment

NCT00457691

Vatalanib plus oxaliplatin/5-FU/leucovorin following previous treatment with irinotecan

NCT00056446

  1. *Note that there are additional phase 3 studies of bevacizumab for the treatment of mCRC.
  2. TKIs = tyrosine kinase inhibitors.
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us